Aberrant cytokine production by nonmalignant cells in the pathogenesis of myeloproliferative tumors and response to jak inhibitor therapies

Cancer Discovery

Volumn 5, Issue 3, 2015, Pages 316-376

  Belver, Laura ^a   Ferrando, Adolfo A ^a,b  

^a Institute for Cancer Genetics Columbia University ^*  (United States)

^b Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; JANUS KINASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RUXOLITINIB; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; STAT PROTEIN;

ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CELL POPULATION; CELLS BY FUNCTION; CYTOKINE PRODUCTION; HUMAN; INTRACELLULAR SIGNALING; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; NONMALIGNANT CELL; PATHOGENESIS; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; ANIMAL; CELL TRANSFORMATION; METABOLISM; MYELOPROLIFERATIVE DISORDER; SIGNAL TRANSDUCTION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; JANUS KINASES; MYELOPROLIFERATIVE DISORDERS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84925304683     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-0095     Document Type: Article

References (7)

1. Viny AD, Levine RL. Genetics of myeloproliferative neoplasms. Cancer J 2014;20:61–5.
2. Kleppe M, Levine RL. New pieces of a puzzle: the current biological picture of MPN. Biochim Biophys Acta 2012;1826:415–22.
3. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stal-bovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Eng J Med 2012;366:787–98.
4. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 2014;120:513–20.
5. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofi brosis: a comprehensive cytokine profiling study. J Clin Oncol 2011;29:1356–63.
6. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and effi cacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofi brosis. N Eng J Med 2010; 363: 1117–27.
7. Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, et al. JAK–STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov 2015;5:316–31.